NCT02489903 2025-03-17RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)EpicentRx, Inc.Phase 2 Completed139 enrolled 14 charts
NCT00537511 2019-11-19A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and EtoposideCelgenePhase 1/2 Terminated22 enrolled 13 charts